Sidley Represents Respira in Its Option to Be Acquired by Gossamer Bio
September 30, 2025
Related Professionals
Related Capabilities
SERVICES AND INDUSTRIES
Stay Up To Date
Sidley represented Respira Therapeutics, Inc., a Samsara BioCapital portfolio company, in its agreement granting an option to Gossamer Bio, Inc. (Nasdaq: GOSS) to acquire the company. Respira is developing RT234 (vardenafil inhalation powder) as the first as-needed therapy for use in pulmonary hypertension.
The Sidley team was led by partner Jason Kropp and counsel Rebecca Nauta (Emerging Companies and Venture Capital), and included Dr. Christian Brause and Andy Lau (Tax); Nicholas Frey (Employee Benefits and Executive Compensation); Lauren Grau (Technology and Life Sciences Transactions); and Ethan McMahon and Margalit Zimand (M&A).
This website uses cookies. Analytical cookies help us improve our website by providing insight on how visitors interact with our site, and necessary cookies which the website needs to function properly.
Necessary Cookies
The website cannot function properly without these necessary cookies, and they can only be disabled by changing your browser preferences. To learn more about these cookies, how we use them on our website, and how to revise your cookie settings, please view our cookie policy.
You have successfully set your edition to United States. Would you like to make this selection your default edition?
*Selecting a default edition will set a cookie.
This website uses cookies. Analytical cookies help us improve our website by providing insight on how visitors interact with our site, and necessary cookies which the website needs to function properly.
Necessary Cookies
The website cannot function properly without these necessary cookies, and they can only be disabled by changing your browser preferences. To learn more about these cookies, how we use them on our website, and how to revise your cookie settings, please view our cookie policy.